Trial Recruitment Closes On Novo’s Next Big Semaglutide Bet: Alzheimer’s Disease
Twin EVOKE Studies Aim To Prove Neurological Benefits
Executive Summary
Semaglutide has become a game-changer in type 2 diabetes and overweight patients, but Novo Nordisk is hoping to prove it can also slow cognitive decline in Alzheimer’s disease. It’s a long shot, but two large Phase III studies are now well underway to show just that.
You may also be interested in...
Lilly’s Donanemab, Now At FDA, Poised To Join Alzheimer’s Armamentarium
Lilly expects US approval of the anti-amyloid therapy by the end of the year. Full Phase III data were detailed at AAIC.
Genentech Joins Hunt For ‘Molecular Glue’ Drugs With Orionis
Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.
RayzeBio And Genentech Show Interest In Radiopharmaceuticals Continues To Grow
RayzeBio's IPO and Genentech's first buy-in into the field show a wave of next-generation companies hoping to expand the radiopharmaceutical field.